MorphoSys and Incyte announce the acceptance of the Swissmedic marketing authorisation application for tafasitamab

MorphoSys

5 January 2021 - The Swissmedic marketing authorisation application seeks approval for tafasitamab in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

MorphoSys and Incyte today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has accepted the marketing authorisation application for tafasitamab, a humanised Fc modified cytolytic CD19 targeting monoclonal antibody.

Read MorphoSys press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Dossier , Switzerland